• Publications
  • Influence
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
The disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL are identified. Expand
Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.
The comparative study indicates that UC is an excellent alternative to BM as a source of MSC for cell therapies, and has a cytokine spectrum very similar to that of BM-MSC. Expand
Nuclear miRNA Regulates the Mitochondrial Genome in the Heart
The data show for the first time that nuclear miR-181c translocates into the mitochondria and regulates mitochondrial genome expression, ultimately causing electron transport chain complex IV remodeling and mitochondrial dysfunction. Expand
MEK and the inhibitors: from bench to bedside
This review summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162, RO5126766, WX-554, RO4987655, GDC-0973 (XL518), and AZD8330, and summarized new MAP kinase signaling pathways involving 7 MEK enzymes. Expand
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors.
  • Z. Wan, N. Zhi, +8 authors N. Young
  • Biology, Medicine
  • The Journal of clinical investigation
  • 1 October 2010
Downstream E2F4/E2F5 targets, which are potentially involved in the progression from G₂ into M phase and erythroid differentiation, were identified by microarray analysis and provide new insight into the molecular pathogenesis of B19V in highly permissive erythyroid progenitors. Expand
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC and HM61713, ASP8237, EGF816, and PF-06747775 are still in early clinical development. Expand
Ibrutinib and novel BTK inhibitors in clinical development
Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials, but additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. Expand
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
A review of recent development in clinical trials testing HDAC inhibitors as anti-tumor agents including both hematological and solid malignancies. Expand
Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone.
This response in the mouse occurs without a measurable decrease in testicular testosterone, suggesting that altered seminiferous cord formation and gonocyte multinucleation may not be mechanistically linked to lowered testosterone. Expand
Novel CD20 monoclonal antibodies for lymphoma therapy
This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumAB (PRO70769), and third-generationmAbs, AME-133v (ocaratuzumAB), PRO131921 and GA101 (obinutumumab). Expand